Drug Profile
Lusupultide
Alternative Names: BY 2001; Lung surfactant factor; Recombinant surfactant protein C; rSP-C; VenticuteLatest Information Update: 02 Apr 2008
Price :
$50
*
At a glance
- Originator Scios
- Developer Nycomed
- Class Phospholipids; Pulmonary surfactants; Recombinant proteins; Surfactants
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Adult respiratory distress syndrome
Most Recent Events
- 01 Jun 2007 Lusupultide received Fast Track designation for Adult respiratory distress syndrome [Intratracheal] in the US
- 02 Sep 2004 A study has been added to the Respiratory Tract Disorders therapeutic trials section
- 16 Jun 2004 Phase-III clinical trials in Adult respiratory distress syndrome in European Union (Intratracheal)